SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

Core Viewpoint - SCYNEXIS is conducting a corporate update call to discuss its financial outlook, clinical results, and business strategy for the future [2]. Group 1 - The call includes forward-looking statements based on current expectations, which may differ materially from actual results due to risks and uncertainties [2]. - The company emphasizes that all forward-looking statements are valid only as of March 31, 2026, and it has no obligation to update these statements after this date [3].